MacroGenics Competitors

Ultragenyx Pharmaceutical (NASDAQ:RARE) and MacroGenics (NASDAQ:MGNX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Volatility & Risk

Ultragenyx Pharmaceutical has a beta of 2.19, meaning that its stock price is 119% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 2.4, meaning that its stock price is 140% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Ultragenyx Pharmaceutical and MacroGenics, as reported by MarketBeat.

Ultragenyx Pharmaceutical currently has a consensus target price of $131.20, suggesting a potential upside of 26.79%. MacroGenics has a consensus target price of $33.30, suggesting a potential upside of 6.87%. Given Ultragenyx Pharmaceutical's higher probable upside, equities analysts clearly believe Ultragenyx Pharmaceutical is more favorable than MacroGenics.

Insider & Institutional Ownership

95.8% of MacroGenics shares are owned by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 9.0% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Ultragenyx Pharmaceutical and MacroGenics' gross revenue, earnings per share and valuation.

MacroGenics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ultragenyx Pharmaceutical and MacroGenics' net margins, return on equity and return on assets.

Summary

MacroGenics beats Ultragenyx Pharmaceutical on 8 of the 14 factors compared between the two stocks.

GW Pharmaceuticals (NASDAQ:GWPH) and MacroGenics (NASDAQ:MGNX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Valuation & Earnings

This table compares GW Pharmaceuticals and MacroGenics' gross revenue, earnings per share and valuation.

GW Pharmaceuticals has higher revenue and earnings than MacroGenics. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for GW Pharmaceuticals and MacroGenics, as reported by MarketBeat.

GW Pharmaceuticals currently has a consensus target price of $204.0909, suggesting a potential downside of 6.35%. MacroGenics has a consensus target price of $33.30, suggesting a potential upside of 6.87%. Given MacroGenics' stronger consensus rating and higher probable upside, analysts clearly believe MacroGenics is more favorable than GW Pharmaceuticals.

Profitability

This table compares GW Pharmaceuticals and MacroGenics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

81.0% of GW Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.8% of MacroGenics shares are owned by institutional investors. 3.1% of GW Pharmaceuticals shares are owned by insiders. Comparatively, 9.0% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

GW Pharmaceuticals has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 2.4, meaning that its stock price is 140% more volatile than the S&P 500.

Summary

MacroGenics beats GW Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

MacroGenics (NASDAQ:MGNX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Valuation and Earnings

This table compares MacroGenics and Ascendis Pharma A/S's gross revenue, earnings per share and valuation.

MacroGenics has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for MacroGenics and Ascendis Pharma A/S, as reported by MarketBeat.com.

MacroGenics presently has a consensus target price of $33.30, suggesting a potential upside of 6.87%. Ascendis Pharma A/S has a consensus target price of $187.6667, suggesting a potential upside of 49.40%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than MacroGenics.

Profitability

This table compares MacroGenics and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Insider and Institutional Ownership

95.8% of MacroGenics shares are owned by institutional investors. 9.0% of MacroGenics shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

MacroGenics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Summary

MacroGenics beats Ascendis Pharma A/S on 8 of the 14 factors compared between the two stocks.

MacroGenics (NASDAQ:MGNX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Valuation and Earnings

This table compares MacroGenics and Arrowhead Pharmaceuticals' gross revenue, earnings per share and valuation.

Arrowhead Pharmaceuticals has higher revenue and earnings than MacroGenics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MacroGenics and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for MacroGenics and Arrowhead Pharmaceuticals, as reported by MarketBeat.com.

MacroGenics presently has a consensus target price of $33.30, suggesting a potential upside of 6.87%. Arrowhead Pharmaceuticals has a consensus target price of $85.3077, suggesting a potential upside of 37.26%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than MacroGenics.

Risk and Volatility

MacroGenics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.

Insider and Institutional Ownership

95.8% of MacroGenics shares are owned by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 9.0% of MacroGenics shares are owned by insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Arrowhead Pharmaceuticals beats MacroGenics on 10 of the 14 factors compared between the two stocks.

MacroGenics (NASDAQ:MGNX) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Valuation & Earnings

This table compares MacroGenics and TG Therapeutics' revenue, earnings per share and valuation.

MacroGenics has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MacroGenics and TG Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for MacroGenics and TG Therapeutics, as reported by MarketBeat.

MacroGenics presently has a consensus price target of $33.30, suggesting a potential upside of 6.87%. TG Therapeutics has a consensus price target of $64.00, suggesting a potential upside of 42.89%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TG Therapeutics is more favorable than MacroGenics.

Volatility and Risk

MacroGenics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500.

Insider & Institutional Ownership

95.8% of MacroGenics shares are owned by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are owned by institutional investors. 9.0% of MacroGenics shares are owned by company insiders. Comparatively, 13.2% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

MacroGenics beats TG Therapeutics on 9 of the 14 factors compared between the two stocks.

MacroGenics (NASDAQ:MGNX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Valuation & Earnings

This table compares MacroGenics and Ionis Pharmaceuticals' revenue, earnings per share and valuation.

Ionis Pharmaceuticals has higher revenue and earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MacroGenics and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for MacroGenics and Ionis Pharmaceuticals, as reported by MarketBeat.

MacroGenics presently has a consensus price target of $33.30, suggesting a potential upside of 6.87%. Ionis Pharmaceuticals has a consensus price target of $57.9091, suggesting a potential upside of 36.71%. Given Ionis Pharmaceuticals' higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than MacroGenics.

Volatility and Risk

MacroGenics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Insider & Institutional Ownership

95.8% of MacroGenics shares are owned by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are owned by institutional investors. 9.0% of MacroGenics shares are owned by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Ionis Pharmaceuticals beats MacroGenics on 8 of the 14 factors compared between the two stocks.